You are here

Celecoxib/Amlodipine Combo Simultaneously Treats OA Pain and Hypertension in Phase 3 Study

Treatment has beneficial effects on renal function

Positive results have been reported from a phase 3 study of KIT-302 (Kitov Pharmaceuticals), a combination of the nonsteroidal anti-inflammatory drug (NSAID) celecoxib and the calcium channel blocker (CCB) amlodipine besylate. The investigational medication was designed to treat OA pain along with hypertension, a common adverse effect of stand-alone OA pain drugs. The study results suggest that KIT-302 may have beneficial effects on renal function. Damage to renal function can be a serious adverse effect of NSAIDs.

Further analysis of data obtained in the phase 3 study, of which top line results were announced in December 2015, showed that celecoxib increased serum creatinine levels compared with placebo. In contrast, while amlodipine alone reduced serum creatinine (–2.55 mcmol/L), a greater reduction in plasma levels of creatinine was achieved in patients receiving KIT-302 (–3.22 mcmol/L), suggesting better renal function.

Additional data supporting the conclusion that KIT-302 may have a beneficial effect on renal function included measurements of peripheral edema, a known adverse effect of CCBs, such as amlodipine. Peripheral edema was reported in 15.6% of patients receiving amlodipine compared with 8.2% of patients receiving KIT-302. These data suggest that KIT-302 may protect against amlodipine’s potential to cause renal fluid retention, according to Kitov Pharmaceuticals.

The phase 3, double-blind, placebo-controlled trial protocol was designed to quantify the reduction in hypertension in patients receiving KIT-302. The study was conducted in the United Kingdom in four groups of 26 to 49 patients each, with a total of 152 patients participating in the trial. Each patient was treated for two weeks. Group 1 received KIT-302; group 2 received amlodipine besylate only; and group 3 received celecoxib only. Group 4 was treated with a double placebo.

The study’s primary objective was to show that a combination of the two components of KIT-302 (group 1) lowers daytime systolic blood pressure (SBP) by at least 50% of the reduction in blood pressure achieved in patients receiving amlodipine alone (group 2). The final results showed a mean reduction in daytime SBP of 8.8 mm Hg in the amlodipine group compared with a reduction of 10.6 mm Hg in the KIT-302 group (P = 0.001).

Source: Kitov Pharmaceuticals; June 24, 2016. 

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs